These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 36150947)

  • 1. Chop-Chop: The Future of Bacterial Enzymes in Transfusion Medicine.
    Klontz EH
    Transfus Med Rev; 2022 Oct; 36(4):246-251. PubMed ID: 36150947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful treatment of experimental glomerulonephritis with IdeS and EndoS, IgG-degrading streptococcal enzymes.
    Yang R; Otten MA; Hellmark T; Collin M; Björck L; Zhao MH; Daha MR; Segelmark M
    Nephrol Dial Transplant; 2010 Aug; 25(8):2479-86. PubMed ID: 20219834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using imlifidase to elucidate the characteristics and importance of anti-GBM antibodies produced after start of treatment.
    Tyrberg L; Andersson F; Uhlin F; Hellmark T; Segelmark M
    Nephrol Dial Transplant; 2023 Dec; 39(1):45-54. PubMed ID: 37385828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-glomerular basement membrane disease (Goodpasture disease): From pathogenesis to plasma exchange to IdeS.
    Shin JI; Geetha D; Szpirt WM; Windpessl M; Kronbichler A
    Ther Apher Dial; 2022 Feb; 26(1):24-31. PubMed ID: 34339589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imlifidase: First Approval.
    Al-Salama ZT
    Drugs; 2020 Nov; 80(17):1859-1864. PubMed ID: 33058042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The IgG-degrading enzyme of Streptococcus pyogenes causes rapid clearance of anti-glomerular basement membrane antibodies in patients with refractory anti-glomerular basement membrane disease.
    Soveri I; Mölne J; Uhlin F; Nilsson T; Kjellman C; Sonesson E; Segelmark M
    Kidney Int; 2019 Nov; 96(5):1234-1238. PubMed ID: 31563334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toward Clinical use of the IgG Specific Enzymes IdeS and EndoS against Antibody-Mediated Diseases.
    Collin M; Björck L
    Methods Mol Biol; 2017; 1535():339-351. PubMed ID: 27914091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Streptococcal Enzymes as Precision Tools Against Pathogenic IgG Autoantibodies in Small Vessel Vasculitis.
    Segelmark M; Björck L
    Front Immunol; 2019; 10():2165. PubMed ID: 31616410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IdeS in anti-glomerular basement membrane disease: Is this the new deal?
    Rafat C; Luque Y
    Kidney Int; 2019 Nov; 96(5):1068-1070. PubMed ID: 31648697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-glomerular basement membrane antibody disease treated with rituximab: A case-based review.
    Syeda UA; Singer NG; Magrey M
    Semin Arthritis Rheum; 2013 Jun; 42(6):567-72. PubMed ID: 23352254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Goodpasture syndrome manifesting as nephrotic-range proteinuria with anti-glomerular basement membrane antibody seronegativity: A case report.
    Zhong Z; Tan J; Tang Y; Li Z; Qin W
    Medicine (Baltimore); 2020 Sep; 99(39):e22341. PubMed ID: 32991448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recurrence of Goodpasture syndrome without circulating anti-glomerular basement membrane antibodies after kidney transplant, a case report.
    Thibaud V; Rioux-Leclercq N; Vigneau C; Morice S
    BMC Nephrol; 2019 Jan; 20(1):6. PubMed ID: 30621605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extensive substrate recognition by the streptococcal antibody-degrading enzymes IdeS and EndoS.
    Sudol ASL; Butler J; Ivory DP; Tews I; Crispin M
    Nat Commun; 2022 Dec; 13(1):7801. PubMed ID: 36528711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo enzymatic modulation of IgG antibodies prevents immune complex-dependent skin injury.
    Mihai S; Albert H; Ludwig RJ; Iwata H; Björck L; Collin M; Nimmerjahn F
    Exp Dermatol; 2017 Aug; 26(8):691-696. PubMed ID: 27512946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-glomerular basement membrane nephritis and bullous pemphigoid caused by distinct anti-alpha 3(IV)NC1 and anti-BP180 antibodies in a patient with Crohn's disease.
    Plaisier E; Borradori L; Hellmark T; Wattiaux MJ; Flageul B; Mougenot B; Ronco P
    Am J Kidney Dis; 2002 Sep; 40(3):649-54. PubMed ID: 12200819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IdeS (Imlifidase): A Novel Agent That Cleaves Human IgG and Permits Successful Kidney Transplantation Across High-strength Donor-specific Antibody.
    Lonze BE; Tatapudi VS; Weldon EP; Min ES; Ali NM; Deterville CL; Gelb BE; Benstein JA; Dagher NN; Wu M; Montgomery RA
    Ann Surg; 2018 Sep; 268(3):488-496. PubMed ID: 30004918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-glomerular basement membrane disease mediated by IgG and IgA: a case report.
    Zou G; Lu H; Zhuo L; Zou W; Li W
    Ren Fail; 2021 Dec; 43(1):774-778. PubMed ID: 33913397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Goodpasture's disease: a report of ten cases and a review of the literature.
    Dammacco F; Battaglia S; Gesualdo L; Racanelli V
    Autoimmun Rev; 2013 Sep; 12(11):1101-8. PubMed ID: 23806563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IdeS: a bacterial proteolytic enzyme with therapeutic potential.
    Johansson BP; Shannon O; Björck L
    PLoS One; 2008 Feb; 3(2):e1692. PubMed ID: 18301769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Streptococcal IdeS: therapeutic potential for Guillain-Barré syndrome.
    Takahashi R; Yuki N
    Sci Rep; 2015 Jul; 5():10809. PubMed ID: 26194472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.